{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:24:15Z","timestamp":1757453055920},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,11,1]]},"DOI":"10.2169\/internalmedicine.4699-20","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T22:07:13Z","timestamp":1594678033000},"page":"2711-2717","source":"Crossref","is-referenced-by-count":9,"title":["Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer"],"prefix":"10.2169","volume":"59","author":[{"given":"Masakatsu","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimi","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranji","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoe","family":"Horita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasuku","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motona","family":"Kumagai","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohsuke","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomiyasu","family":"Arisawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Guidelines for medical treatment of lung cancer 2019 edition Japan Lung Cancer Society."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stageIII non-small-cell lung cancer. N Engl J Med 377: 1919-1929, 2017.","DOI":"10.1056\/NEJMoa1709937"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379: 2342-2350, 2018.","DOI":"10.1056\/NEJMoa1809697"},{"key":"4","unstructured":"4. Osta B. El, Hu F, Sadak R, et al. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol 119: 1-12, 2017."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 366: 2517-2519, 2012.","DOI":"10.1056\/NEJMe1205943"},{"key":"6","unstructured":"6. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy- inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 18: 6580-6587, 2012."},{"key":"7","unstructured":"7. Kobayashi T, Iwama S, Yasuda Y, et al. Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study. J Endocr Soc 2: 241-251, 2018."},{"key":"8","unstructured":"8. Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19: 1480-1492, 2018."},{"key":"9","unstructured":"9. AstraZeneca MediChannel. IMFINZI EPPV (early post-marketing phase vigilance) final report 2019. [cited 2020 Feb 19]. Available from: http:\/\/med.astrazeneca.co.jp\/safety\/IMF.html"},{"key":"10","unstructured":"10. AstraZeneca MediChannel. Imfinzi Appropriate use guide. [cited 2020 Feb 19]. Available from: http:\/\/med.astrazeneca.co.jp\/medical\/product\/imf_lc_guide.html"},{"key":"11","unstructured":"11. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) in partnership with the American Society of Clinical Oncology (ASCO): management of immunotherapy-related toxicities. version 1 [Internet]. 2020 [cited 2020 Feb 19]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf"},{"key":"12","unstructured":"12. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28: 119-142, 2017."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 36: 2872-2878, 2018.","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 33: 3193-3198, 2015.","DOI":"10.1200\/JCO.2015.60.8448"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res 6: 1093-1099, 2018.","DOI":"10.1158\/2326-6066.CIR-17-0755"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Sue M, Ueno M, Takabatake H, et al. A case report of pembrolizumab-induced liver injury: the implication of CD8-positive lymphocytes in the immune-related adverse event. Kanzo 59: 571-577, 2018 (in Japanese, Abstract in English).","DOI":"10.2957\/kanzo.59.571"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kleiner D, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 57: 2233-2240, 2012.","DOI":"10.1007\/s10620-012-2140-5"},{"key":"18","unstructured":"18. Nguyen Canh H, Harada K, Ouchi H, et al. Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients. J Clin Pathol 70: 961-969, 2017."},{"key":"19","unstructured":"19. Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol 31: 965-973, 2018."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Cassim S, Bilodeau M, Vincent C, et al. Novel immunotherapies for autoimmune hepatitis. Front Pediatr 5: 8, 2017.","DOI":"10.3389\/fped.2017.00008"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/21\/59_4699-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T03:48:24Z","timestamp":1604720904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/21\/59_4699-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":20,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4699-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}